- Home
- QGEN vs PTGX Comparison
QGEN vs PTGX Comparison
Compare QGEN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QGEN | PTGX |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | Netherlands | United States |
| Employees | N/A | 141 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.3B |
| IPO Year | 1998 | 2016 |
Fundamental Metrics
Financial Performance| Metric | QGEN | PTGX |
|---|---|---|
| Price | $44.62 | $144.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $45.76 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.9M | 470.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $8.18 | $874.25 |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | ★ $24.01 | $61.10 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.53 | $62.24 |
| 52 Week High | $57.82 | $160.81 |
Technical Indicators
Market Signals| Indicator | QGEN | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 58.92 | 48.63 |
| Support Level | $41.34 | $141.95 |
| Resistance Level | $44.72 | $151.24 |
| Average True Range (ATR) | 0.95 | 4.95 |
| MACD | 0.07 | -0.80 |
| Stochastic Oscillator | 89.13 | 40.44 |
Price Performance
Historical ComparisonAbout QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.